Ipsen Beheer
Beheer criteriumcontroles 2/4
De CEO Ipsen is David Loew, benoemd in Jul2020, heeft een ambtstermijn van 5.92 jaar. De totale jaarlijkse vergoeding van { bedraagt € 10.42M, bestaande uit 9.8% salaris en 90.2% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.11% van de aandelen van het bedrijf, ter waarde € 14.35M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.8 jaar en 11.1 jaar.
Belangrijke informatie
David Loew
Algemeen directeur
€10.4m
Totale compensatie
| Percentage CEO-salaris | 9.84% |
| Dienstverband CEO | 5.9yrs |
| Eigendom CEO | 0.1% |
| Management gemiddelde ambtstermijn | 3.8yrs |
| Gemiddelde ambtstermijn bestuur | 11.1yrs |
Recente managementupdates
Recent updates
Narratiefupdate • Jun 29
IPN: Rare Liver Disease And Oncology Portfolio Will Drive Re Rated Earnings Potential
The analyst price target for Ipsen has shifted from €183 to about €211. Analysts point to the company's oncology portfolio, rare liver disease products, and neuroscience offering as the main reasons for the higher valuation assumptions.
Narratiefupdate • Jun 15
IPN: Oncology And Rare Liver Pipeline Progress Will Shape Balanced Future Outlook
The analyst price target for Ipsen has been raised from €151.94 to €159.25. Analysts cite the company's oncology, rare liver disease and neuroscience portfolio, along with profit margin assumptions and P/E expectations, to justify the change.
Narratiefupdate • Jun 01
IPN: Oncology Safety Concerns And Pipeline Uncertainty Will Limit Future Share Upside
Analysts have lifted the Ipsen fair value estimate from €115 to €117, citing higher modeled revenue growth and slightly stronger profit margins, while Street price targets from banks including Deutsche Bank, JPMorgan and BNP Paribas continue to reset higher despite the recent tazemetostat withdrawal. Analyst Commentary Street research signals a mixed picture for Ipsen, with several large banks lifting their price targets while others highlight risks around the tazemetostat withdrawal and future growth execution.Narratiefupdate • May 17
IPN: Future Portfolio Execution And Core Pipeline Will Shape Re Rated Earnings Potential
Analysts have raised Ipsen's price target by €13 to €183, citing updated assumptions around the discount rate, revenue growth, profit margins and future P/E that align with recent upward revisions from major banks. Analyst Commentary Recent research updates point to a more constructive stance on Ipsen, with several bullish analysts revisiting their models and price targets.Narratiefupdate • Apr 24
IPN: Future Portfolio Execution Will Drive Re Rated Earnings Power Potential
Narrative Update on Ipsen The analyst fair value estimate for Ipsen has been revised from €155 to €183. This reflects analysts' updated assumptions on higher revenue growth, a different discount rate, a higher future P/E and recent price target increases and rating changes across several banks.Narratiefupdate • Apr 10
IPN: Oncology Pipeline Progress And Safety Setbacks Will Shape Balanced Future Outlook
Analysts have adjusted the Ipsen price target to €151.94, with recent research pointing to updated revenue growth and profit margin assumptions, as well as fresh Street targets around €160 and €170 as key drivers of the new view. Analyst Commentary Bullish Takeaways Bullish analysts are pointing to higher price targets around €160 and €170, which reflects confidence in Ipsen’s ability to execute on its current pipeline and financial framework despite recent product-specific issues.Narratiefupdate • Mar 27
IPN: Early Oncology Pipeline And Safety Setbacks Will Shape Future Upside
The analyst fair value estimate for Ipsen has shifted from €143 to about €152, as analysts factor in updated price targets around €160 to €170 and recent rating changes that reflect both the impact of the tazemetostat withdrawal and a focus on the broader pipeline and earnings profile. Analyst Commentary Recent research shows a split view on Ipsen, with some bullish analysts lifting price targets toward €160 to €170, while more cautious voices highlight pipeline depth and valuation risks after the tazemetostat withdrawal.Narratiefupdate • Mar 13
IPN: Oncology Setbacks And Limited Late Stage Pipeline Will Constrain Future Upside
The analyst fair value estimate for Ipsen has shifted from €105 to €115, with analysts pointing to recent price target revisions, mixed views on the company’s pipeline depth, and updated assumptions on margins and future P/E levels as key drivers of the change. Analyst Commentary Recent Street research around Ipsen has focused on shifting views of the company’s pipeline and valuation, with mixed reactions to the withdrawal of tazemetostat and differing opinions on the depth of late stage assets.Narratiefupdate • Feb 27
IPN: Limited Late Stage Pipeline Will Constrain Future Upside Potential
The analyst fair value estimate for Ipsen has moved from €134.80 to €143.00, reflecting updated assumptions on revenue growth, margins, and future P/E, following recent price target changes from banks that now range from about €125 to €170. Analyst Commentary Recent research on Ipsen reflects a mix of optimism and caution, with target prices clustering between about €125 and €170 and ratings spread across Buy, Neutral, and Equal Weight.Narratiefupdate • Feb 12
IPN: Competitive Pressures And Thin Pipeline Will Shape A Balanced Outlook
Analysts have increased their fair value estimate for Ipsen to about €135 per share from roughly €133, reflecting updated price targets that incorporate a mix of cautious views on the late stage pipeline and concerns around competitive pressures, alongside modest target increases from others. Analyst Commentary Recent research shows a split view on Ipsen, with some analysts trimming expectations and others nudging targets higher.Narratiefupdate • Jan 29
IPN: Mixed Ratings And Limited Late Stage Assets Will Shape A Balanced Outlook
Narrative Update The updated analyst price target for Ipsen moves modestly higher to about €133 from about €131. Analysts point to slightly stronger revenue growth and margin assumptions, while also flagging ongoing concerns about limited late stage assets and competitive pressure on Somatuline, as reflected in recent mixed rating and target changes from UBS, Barclays, and BNP Paribas Exane.Narratiefupdate • Jan 15
IPN: Mixed Ratings And Pipeline Setbacks Will Shape A Cautious Yet Balanced Outlook
Our updated fair value estimate for Ipsen edges up from €130.07 to €130.79. This reflects a blend of mixed Street signals, where some analysts point to valuation constraints and pipeline depth, while others lift price targets in line with current expectations.Narratiefupdate • Dec 21
IPN: Guidance Upgrade And Competitive Pressures Will Shape A Cautious Yet Balanced Outlook
Analysts have reduced their price target on Ipsen from EUR 130.07 to EUR 105.00, citing increased competitive pressure on Somatuline as a key driver of the downgrade. Analyst Commentary Analysts note that the reduced price target reflects a reassessment of Ipsen's risk and reward profile in light of mounting competition for Somatuline, which is expected to weigh on both top line momentum and margin resilience.Narratiefupdate • Dec 07
IPN: Guidance Upgrade And Competition Concerns Will Shape Balanced Future Outlook
Analysts have trimmed their price target on Ipsen by approximately EUR 1 to around EUR 130, reflecting slightly lower long term growth and margin expectations amid rising competitive pressure on key drug Somatuline. Analyst Commentary Analyst sentiment around Ipsen has turned more cautious, with recent revisions reflecting heightened concern about the sustainability of growth in key endocrine oncology franchises and the implications for valuation.Narratiefupdate • Nov 22
IPN: Guidance Upgrade And New Approvals Will Support Balanced Outlook
Narrative Update on Ipsen Analysts have maintained their fair value estimate for Ipsen at €130.79 per share. They cite minimal changes in key assumptions and only slight fluctuations in projected growth and profitability.Narratiefupdate • Nov 07
IPN: Future Opportunities And Risks Are Balanced Following Guidance Upgrade
Narrative Update on Ipsen: Analyst Price Target Adjustment Analysts have raised their price target for Ipsen to €130.79, up from €129.93. This change reflects slight improvements in expected revenue growth and profit margin, despite a marginally higher discount rate.Analyseartikel • Oct 28
Ipsen (EPA:IPN) Seems To Use Debt Rather Sparingly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Narratiefupdate • Oct 24
Global Approvals And Guidance Will Drive Expanded Patient Access Worldwide
Narrative Update on Ipsen: Analyst Price Target Adjustment Analysts have slightly increased their price target for Ipsen from $128.43 to $129.93. This adjustment is attributed to minor shifts in revenue growth forecasts and updated profit margin estimates.Narratiefupdate • Sep 25
Pipeline Catalysts And Approvals Will Expand Global Access
Driven by a modest uptick in consensus revenue growth forecasts and a slight increase in the projected future P/E, Ipsen’s analyst price target has inched up from €127.00 to €128.43. What's in the News Ipsen received Japanese regulatory approval for Bylvay (odevixibat) for the treatment of pruritus associated with progressive familial intrahepatic cholestasis (PFIC), with commercialization managed by Ipsen in Japan.Analyseartikel • Sep 07
Are Investors Undervaluing Ipsen S.A. (EPA:IPN) By 41%?
Key Insights Ipsen's estimated fair value is €205 based on 2 Stage Free Cash Flow to Equity Current share price of €120...Analyseartikel • Jul 13
Investors Interested In Ipsen S.A.'s (EPA:IPN) Earnings
Ipsen S.A.'s ( EPA:IPN ) price-to-earnings (or "P/E") ratio of 24.5x might make it look like a strong sell right now...
Nieuw narratief • Feb 23
Cabometyx And Tovorafenib Approvals May Strengthen Oncology Portfolio In 2025
Expansion of Onivyde and new product approvals could significantly increase revenue and strengthen market positions in key medical segments.Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Dec 31 2025 | €10m | €1m | €444m |
| Sep 30 2025 | n/a | n/a | €446m |
| Jun 30 2025 | n/a | n/a | €448m |
| Mar 31 2025 | n/a | n/a | €402m |
| Dec 31 2024 | €5m | €1m | €356m |
| Jun 30 2024 | n/a | n/a | €664m |
| Mar 31 2024 | n/a | n/a | €641m |
| Dec 31 2023 | €4m | €988k | €617m |
| Jun 30 2023 | n/a | n/a | €406m |
| Mar 31 2023 | n/a | n/a | €500m |
| Dec 31 2022 | €4m | €950k | €593m |
| Sep 30 2022 | n/a | n/a | €656m |
| Jun 30 2022 | n/a | n/a | €719m |
| Mar 31 2022 | n/a | n/a | €675m |
| Dec 31 2021 | €5m | €950k | €631m |
| Sep 30 2021 | n/a | n/a | €626m |
| Jun 30 2021 | n/a | n/a | €622m |
| Mar 31 2021 | n/a | n/a | €585m |
| Dec 31 2020 | €5m | €475k | €548m |
Compensatie versus markt: De totale vergoeding ($USD 11.88M ) David } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de French markt ($USD 5.65M ).
Compensatie versus inkomsten: De vergoeding van David is het afgelopen jaar met meer dan 20% gestegen.
CEO
David Loew (59 yo)
5.9yrs
Tenure
€10,417,318
Compensatie
Mr. David Loew has been the Chief Executive Officer & MD of Ipsen S.A. since July 1, 2020 and serves as its Director since May 28, 2020. Mr. Loew served as an Executive Vice President of Sanofi Pasteur at...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| MD, CEO & Director | 5.9yrs | €10.42m | 0.11% € 14.3m | |
| Executive VP & CFO | 11.6yrs | €1.02m | geen gegevens | |
| Executive VP & Head of Technical Operations | less than a year | geen gegevens | geen gegevens | |
| Global Vice President of Investor Relations | no data | geen gegevens | geen gegevens | |
| Executive VP & General Counsel | less than a year | geen gegevens | geen gegevens | |
| Head of Global Media Relations | no data | geen gegevens | geen gegevens | |
| Executive VP & Chief Human Resources Officer | 8.3yrs | geen gegevens | geen gegevens | |
| Executive VP & Chief Business Officer | 5.7yrs | geen gegevens | geen gegevens | |
| Executive VP | 4.6yrs | geen gegevens | geen gegevens | |
| Executive VP & Chief Medical Officer | 3.1yrs | geen gegevens | geen gegevens | |
| Executive VP and Head of R&D | 2.8yrs | geen gegevens | geen gegevens | |
| Executive VP & Chief Corporate Affairs Officer | 1.8yrs | geen gegevens | geen gegevens |
3.8yrs
Gemiddelde duur
57yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van IPN wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| MD, CEO & Director | 6.1yrs | €10.42m | 0.11% € 14.3m | |
| Non-Executive Chairman | 15.6yrs | €600.00k | 0.16% € 22.2m | |
| Independent Director | 9yrs | €170.00k | 0.00084% € 113.8k | |
| Director | 11.1yrs | €110.95k | 0.00061% € 82.6k | |
| Vice Chairman | 20.8yrs | €189.32k | 0.0037% € 494.4k | |
| Director | 20.8yrs | €60.00k | 26.57% € 3.6b | |
| Independent Director | no data | €135.00k | geen gegevens | |
| Director | 14yrs | €170.35k | 0.00061% € 82.6k | |
| Director | 14.4yrs | €155.00k | geen gegevens | |
| Independent Director | 2.7yrs | €170.00k | 0.00061% € 82.6k | |
| Employees Representative Director | 5.6yrs | geen gegevens | 0.0016% € 222.2k | |
| Employee Representative Director | 4.1yrs | geen gegevens | 0.0042% € 570.3k |
11.1yrs
Gemiddelde duur
62.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van IPN zijn ervaren en ervaren (gemiddelde ambtstermijn van 11.1 jaar).
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/06/30 19:51 |
| Aandelenkoers aan het einde van de dag | 2026/06/30 00:00 |
| Inkomsten | 2025/12/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Ipsen S.A. wordt gevolgd door 26 analisten. 12 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Richard Silver | Barclays |
| Charles Pitman | Barclays |
| Yihan Li | Barclays |